

PCR MIB Trial News

www.anzup.org.au

Welcome to our third PCR MIB newsletter

8 patients are now registered to the study, 25% of the recruitment target. Congratulations everyone involved in reaching this milestone.


Welcome to Royal North Shore Hospital, joining the study on the 1st of November. We look forward to welcoming Liverpool Hospital soon as well, which is eagerly awaiting activation.

Thanks again to all our sites for helping us reach the 25% target, next stop 50%

Site Update


Site	# Patients Pre-Screened	# Patients Screened	# Patients Registered
AUS		7	4
COL		4	1
POW	1	5	1
SCG	4	6	2
TOTAL:	5	22	8

Prince of Wales Hospital has registered it's first patient to PCR MIB and Austin Hospital has registered it's 4th patient, taking total registrations to 25% of recruitment target.



Message from the PI

Recent presentations at scientific meetings support the approach of combining immunotherapy with chemoradiation in bladder cancer. Two recent presentations at ASCO, and updated at ESMO show that the pathological complete response rate to PD/PD-L1 blockade are between 30-40% when the drug is given neoadjuvantly to patients prior to cystectomy. This suggests the drugs are active in muscle invasive non metastatic disease. Furthermore, updated data from the PACIFIC trial in lung cancer of giving PD-L1 inhibition after chemoradiation show a strong benefit from treatment in improvement in PFS and OS. This data supports the approach being used in the PCR-MIB trial using PD1 inhibition with radiation. Hopefully with more sites added to the study we can complete recruitment in a timely fashion.



ANZUP is continuing to increase awareness of the PCR MIB study with their urological colleagues and discussion at urological forums including ANZUP's Annual Scientific Meeting and Community Engagement Forum. Recruitment rates are also expected to increase with the opening of two new sites – Royal North Shore Hospital and Liverpool Hospital. ANZUP also has all their trials posted on ANZUP ClinTrials Refer app which provides a list of all trials in cancer centres in ANZ. It is designed for oncologists, GP's, trial staff and patients, the ANZUP app has searchable clinical trial details, hospital locations, contacts, inclusion/exclusion criteria and lay summaries. A national ClinTrial App is in development with a demo version on the horizon.

Protocol Version 5.0

Sir Charles Gairdner has obtained Governance approval for protocol version 5.0. All sites are now operating off protocol version 5.0 which is the current version of the protocol.

PCR-MIB Data Management:

Response to data queries - It is important to remember to log into the PCR-MIB Viedoc database regularly to review data queries and respond in a timely manner.

PCR MIB is a collaboration between ANZUP and BaCT



PCR MIB key contacts

Clinical trial operations, BaCT Amanda Seegum E: amanda.seegum@petermac.org T: +61 3 8559 8296

Sponsor queries (payments, contracts) Simran Chawla E: simran.chawla@anzup.org.au T: +61 2 8036 5271

Coordinating PI: Andrew Weikhardt E: andrew.weikhardt@onjcri.org.au

Trial pages: <https://www.anzup.org.au/content.aspx?page=pcrmibtrial>

ANZUP ClinTrial Refer app available for download from iTunes and Google Play